Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Jubilant, Sanofi in Strategic Metabolic Alliance | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Jubilant, Sanofi in Strategic Metabolic Alliance

Aims to develop small molecules to address unmet needs in diabetes and obesity

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Jubilant Biosys Ltd, a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd, and Sanofi Deutschland GmbH, have entered a strategic alliance to discover and develop small molecule inhibitors for multiple targets in metabolic disorders. The research alliance aims to develop therapeutic small molecules that will address the unmet needs in diabetes and obesity.
Jubilant will provide drug discovery and early development services across computational, synthetic chemistry, biology, GLP/ GMP services, to identify lead candidates and demonstrate clinical proof of mechanism. The research for the projects take place at R&D labs of Jubilant Biosys and Jubilant Chemsys (Noida, India).
 
Dr. Sriram Rajagopal, chief scientific officer, Jubilant Biosys said, “We are excited to partner with Sanofi, one of the global healthcare leader, to offer our integrated drug discovery solutions. Over the past few years, we have been strengthening our therapeutic area expertise in the scientific perspective and this collaboration is a validation of our efforts. This alliance demonstrates Jubilant’s commitment to global innovation and we look forward to a long mutually beneficial partnership.”
 
Dr. Philip Just Larsen, vice president, global head of Diabetes Research & Translational Medicine, Sanofi Deutschland GmbH said, “The collaboration with Jubilant underscores our commitment to engaging innovators around the world, as we develop the next generation of improved therapies for people with diabetes.”
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics